• NMPA accepted Alebund’s China NDA for AP301 capsules to treat hyperphosphatemia in chronic kidney disease patients on maintenance dialysis.
• Filing backed mainly by RESPOND-1, a China Phase III trial that met primary endpoints, showing non-inferiority to sevelamer carbonate at week 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals (Jiangsu) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12277109), on August 07, 2026, and is solely responsible for the information contained therein.